FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2516956232> ?p ?o ?g. }

• W2516956232 abstract "Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma and includes an aggressive, PAX3-FOXO1 fusion-positive subtype. Amplification of chromosomal region 12q13-q14, which contains the CDK4 proto-oncogene, was identified in a subset of fusion-positive RMS. Other tumor types with CDK4 amplification or overexpression, including liposarcoma and neuroblastoma, are sensitive to CDK4/6 inhibition, suggesting that CDK4/6-targeted therapies may provide a new treatment strategy in fusion-positive RMS. To evaluate the role of CDK4 in chromosomal region 12q13-14 amplification in fusion-positive RMS and the potential clinical utility of CDK4/6 inhibition in this disease setting, we examined the biological consequences of CDK4 knockdown, CDK4 overexpression, and pharmacologic CDK4/6 inhibition in fusion-positive RMS in vitro and in vivo. Knockdown of CDK4 abrogated proliferation and transformation of 12q13-14-amplified and non-amplified fusion-positive RMS cells via G1-phase cell cycle arrest. This arrest was associated with reduced RB phosphorylation and E2F-responsive gene expression. Significant differences in E2F target expression, however, were not observed in RMS cells overexpressing CDK4 or in fusion-positive tumors harboring 12q13-14 amplification relative to control cells or tumors lacking amplification, respectively. Treatment with the small molecule CDK4/6 inhibitor LEE011 phenocopied CDK4 knockdown, decreasing viability, RB phosphorylation, and E2F-responsive gene expression and inducing G1-phase cell cycle arrest. All fusion-positive RMS cell lines showed sensitivity to CDK4/6 inhibition, with evidence of differential antitumor activity resulting from an inverse relationship between CDK4 expression and inhibitor vulnerability. This variable responsiveness to LEE011 was recapitulated in xenograft models of CDK4-amplified and non-amplified fusion-positive RMS. Our findings demonstrate that CDK4 is necessary for RB-E2F-mediated G1-phase cell cycle progression, proliferation, and transformation in fusion-positive RMS regardless of CDK4 amplification status. Our studies further indicate that single-agent LEE011 is active in the setting of fusion-positive RMS and suggest that CDK4 amplification may be a marker of reduced sensitivity whereas low CDK4 expression may be associated with higher susceptibility to CDK4/6 inhibition. Collectively, our data provide preclinical evidence supporting further investigation of CDK4/6-targeted therapies in treatment regimens for fusion-positive RMS. Citation Format: Mary E. Olanich, Wenyue Sun, Stephen M. Hewitt, Zied Abdullaev, Svetlana D. Pack, Frederic G. Barr. CDK4 amplification reduces sensitivity to CDK4/6 inhibition in fusion-positive rhabdomyosarcoma. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3093. doi:10.1158/1538-7445.AM2015-3093" @default.
• W2516956232 created "2016-09-16" @default.
• W2516956232 creator A5011055578 @default.
• W2516956232 creator A5018687194 @default.
• W2516956232 creator A5025441472 @default.
• W2516956232 creator A5026719110 @default.
• W2516956232 creator A5043895259 @default.
• W2516956232 creator A5074821477 @default.
• W2516956232 date "2015-08-01" @default.
• W2516956232 modified "2023-09-26" @default.
• W2516956232 title "Abstract 3093: CDK4 amplification reduces sensitivity to CDK4/6 inhibition in fusion-positive rhabdomyosarcoma" @default.
• W2516956232 doi "https://doi.org/10.1158/1538-7445.am2015-3093" @default.
• W2516956232 hasPublicationYear "2015" @default.
• W2516956232 type Work @default.
• W2516956232 sameAs 2516956232 @default.
• W2516956232 citedByCount "0" @default.
• W2516956232 crossrefType "proceedings-article" @default.
• W2516956232 hasAuthorship W2516956232A5011055578 @default.
• W2516956232 hasAuthorship W2516956232A5018687194 @default.
• W2516956232 hasAuthorship W2516956232A5025441472 @default.
• W2516956232 hasAuthorship W2516956232A5026719110 @default.
• W2516956232 hasAuthorship W2516956232A5043895259 @default.
• W2516956232 hasAuthorship W2516956232A5074821477 @default.
• W2516956232 hasConcept C104317684 @default.
• W2516956232 hasConcept C105696609 @default.
• W2516956232 hasConcept C111829193 @default.
• W2516956232 hasConcept C142724271 @default.
• W2516956232 hasConcept C1491633281 @default.
• W2516956232 hasConcept C153911025 @default.
• W2516956232 hasConcept C173396325 @default.
• W2516956232 hasConcept C2778256501 @default.
• W2516956232 hasConcept C2780844630 @default.
• W2516956232 hasConcept C2781018059 @default.
• W2516956232 hasConcept C29537977 @default.
• W2516956232 hasConcept C502942594 @default.
• W2516956232 hasConcept C54355233 @default.
• W2516956232 hasConcept C71924100 @default.
• W2516956232 hasConcept C7602840 @default.
• W2516956232 hasConcept C81885089 @default.
• W2516956232 hasConcept C83258922 @default.
• W2516956232 hasConcept C86803240 @default.
• W2516956232 hasConceptScore W2516956232C104317684 @default.
• W2516956232 hasConceptScore W2516956232C105696609 @default.
• W2516956232 hasConceptScore W2516956232C111829193 @default.
• W2516956232 hasConceptScore W2516956232C142724271 @default.
• W2516956232 hasConceptScore W2516956232C1491633281 @default.
• W2516956232 hasConceptScore W2516956232C153911025 @default.
• W2516956232 hasConceptScore W2516956232C173396325 @default.
• W2516956232 hasConceptScore W2516956232C2778256501 @default.
• W2516956232 hasConceptScore W2516956232C2780844630 @default.
• W2516956232 hasConceptScore W2516956232C2781018059 @default.
• W2516956232 hasConceptScore W2516956232C29537977 @default.
• W2516956232 hasConceptScore W2516956232C502942594 @default.
• W2516956232 hasConceptScore W2516956232C54355233 @default.
• W2516956232 hasConceptScore W2516956232C71924100 @default.
• W2516956232 hasConceptScore W2516956232C7602840 @default.
• W2516956232 hasConceptScore W2516956232C81885089 @default.
• W2516956232 hasConceptScore W2516956232C83258922 @default.
• W2516956232 hasConceptScore W2516956232C86803240 @default.
• W2516956232 hasLocation W25169562321 @default.
• W2516956232 hasOpenAccess W2516956232 @default.
• W2516956232 hasPrimaryLocation W25169562321 @default.
• W2516956232 hasRelatedWork W1785629222 @default.
• W2516956232 hasRelatedWork W1985335364 @default.
• W2516956232 hasRelatedWork W1990750564 @default.
• W2516956232 hasRelatedWork W1999035466 @default.
• W2516956232 hasRelatedWork W2000427166 @default.
• W2516956232 hasRelatedWork W2007995905 @default.
• W2516956232 hasRelatedWork W2112521155 @default.
• W2516956232 hasRelatedWork W2286555654 @default.
• W2516956232 hasRelatedWork W2407148581 @default.
• W2516956232 hasRelatedWork W2550841284 @default.
• W2516956232 hasRelatedWork W2599161212 @default.
• W2516956232 hasRelatedWork W2740267586 @default.
• W2516956232 hasRelatedWork W2890791082 @default.
• W2516956232 hasRelatedWork W2929540441 @default.
• W2516956232 hasRelatedWork W2955082821 @default.
• W2516956232 hasRelatedWork W2955095473 @default.
• W2516956232 hasRelatedWork W2956114772 @default.
• W2516956232 hasRelatedWork W2987101137 @default.
• W2516956232 hasRelatedWork W2992269847 @default.
• W2516956232 hasRelatedWork W3213907495 @default.
• W2516956232 isParatext "false" @default.
• W2516956232 isRetracted "false" @default.
• W2516956232 magId "2516956232" @default.
• W2516956232 workType "article" @default.